Loading clinical trials...
Loading clinical trials...
To examine the quality of liver images produced when the contrast agent Eovist is used during MRI.
Researchers will review data from the Eovist MRI and compare the scan with previous MRI exams the patient had with the same or other contrast agents. To determine the efficacy of Eovist contrast agent in producing MRI images of the liver. We will monitor patients for any unusual symptoms (adverse events) when the contrast is given. Patients are asked to hold their breath during an MRI scan. Eovist may interfere with the "breath hold" which could result in more breathing artifacts (based on a qualitative scale) on arterial images when the patients are given Eovist vs. other contrast agents.
Age
21 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Michigan Hospital
Ann Arbor, Michigan, United States
Start Date
December 1, 2011
Primary Completion Date
August 1, 2016
Completion Date
October 1, 2016
Last Updated
December 16, 2016
198
ACTUAL participants
Eovist Contrast
PROCEDURE
Non Eovist Contrast
PROCEDURE
Lead Sponsor
University of Michigan
NCT07480057
NCT07237750
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06181409